ArticleTurkish journal of medical sciences2019

The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases

Can Türk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.